The p53 signaling pathway works as a potent barrier to tumor progression. Two single nucleotide polymorphisms (SNPs) in the gene loci of p53 pathway, p53 codon 72 Arg72Pro and MDM2 SNP309 (T > G), have been shown to cause perturbation of p53 function, but the effect of the two SNPs on the risk of hepatocellular carcinoma (HCC) remains inconsistent. This study investigated the influence of combined p53 Arg72Pro and MDM2 SNP309 on the risk of developing HCC in patients with chronic hepatitis B virus infection, and evaluated the significance of the two combined SNPs on patient prognosis. In total, 350 HCC patients, 230 non-HCC patients, and 96 healthy controls were genotyped for the p53 Arg72Pro and MDM2 SNP309. The combined p53 Pro/Pro and MDM2 G/G genotype was significantly associated with HCC risk (P = 0.047). Multivariate analysis indicated that combined p53 Pro/Pro and MDM2 G/G genotype was an independent factor affecting recurrence and survival (P < 0.05). Patients with combined p53 Pro/Pro and MDM2 G/G genotypes had a poorer prognosis than other genotypes, P < 0.01 for both disease-free survival (DFS) and overall survival (OS). DFS and OS rates also differed significantly between Barcelona Clinic Liver Cancer (BCLC) stage A patients with combined p53 Pro/Pro and MDM2 G/G and other genotypes (P < 0.05). Thus, the combined p53 Pro/Pro and MDM2 G/G genotype is associated with increased risk of developing HCC and is an independent adverse prognostic indicator in early stage HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer mortality (Parkin, 2001) . The risk factors associated with HCC include alcohol abuse and aflatoxins adduct (Blonski et al., 2010) but the major risk is chronic viral hepatitis, both B and C (Sherman, 2005; El-Serag and Rudolph, 2007) . About 80% of all cases of HCC worldwide are found in Asia and China alone accounts for 55% (Lai and Lau, 2005; El-Serag and Rudolph, 2007) . In Asia, infection with the chronic hepatitis B virus (HBV) is the most important etiologic factor of HCC (Yuen et al., 2009 ). Viral factors (Silini et al., 1996; Kao et al., 2000; Lin and Kao, 2008) and host factors (Clifford et al., 2010; Nault and Zucman-Rossi, 2011 ) modify the devel-opment, progression and clinical outcome of HCC. The risk of HCC is increased in patients with higher levels of HBV replication, determined by tests for hepatits B e antigen (HBeAg) and levels of HBV DNA. Over the last three decades, several mechanisms have been described for the role of HBV in causing HCC including HBV DNA integration in the host genome or transactivation of oncogenes of the host by HBV X protein (HBx) or by another truncated protein derived from the pre-S2/S region of HBV genome (Anzola, 2004; Brechot, 2004; Neuveut et al., 2010) . Indirect mechanisms have also been suggested such as HBV causing chronic hepatic injury and hepatocyte regeneration (Anzola, 2004; Brechot, 2004; Neuveut et al., 2010) .
p53, the most important tumor suppressor gene, lies at critical joint of the complex signaling network for response to stress, playing a major role in hepatocarcinogenesis, irrespective of the etiology (Buendia, 2000; Edamoto et al., 2003) . It is the most common mutated genes of human malignancy. Somatic mutation of p53 is found in 32% of all human liver tumor cases (Petitjean et al., 2007) . The integrity of p53 is an especially important barrier for HBV related HCC development. Integration of HBV DNA in human genome is common and the integration is correlated to chromosome instability (Hino et al., 1991; Brechot, 2004) . Therefore, it is assumed that chronic HBV infection is correlated to prolongation period of DNA damage, which requires the p53 function for DNA repairing. The p53 integrity is likely an important factor reducing DNA damage caused by HBV integration during tumorigenesis (Puisieux et al., 1995) .
Functional inherited single nucleotide polymorphisms (SNPs) exist in the gene loci of the p53 signaling pathway, affecting the cancer risk and clinical outcome (Grochola et al., 2010) . The 215 G > C polymorphisms at codon72 of p53 (Pro72Arg, rs1042522) have been studied in many cancers (Boersma et al., 2006; Han et al., 2008; Horikawa et al., 2008) . It has been reported that this polymorphism influences the transcription, senescence and apoptotic function of p53. The functional impact of the Pro72 variant on apoptotic response, which has been replicated in independent investigations (Baptiste et al., 2002; Dumont et al., 2003; Pim and Banks, 2004) , is a lowered ability of the Pro72 variant to localize to the mitochondria, and this localization is accompanied by the release of cytochrome c into the cytosol (Dumont et al., 2003) . However, the Pro72 variant appears to induce a higher level of G1 arrest than the Arg72 variant (Pim and Banks, 2004) .
MDM2, a negative regulator of p53, is elevated in many cancers that retain wild type p53. MDM2 binds directly to the N-terminus of p53 and negatively regulates the transcriptional activation function of p53. Further, MDM2 could act as an E3 ubiquitin ligase that targets p53 for ubiquitin modification and targeting it to proteasomal degradation (Haupt et al., 1997; Kubbutat et al., 1997) . Upregulated MDM2, therefore, would lead to more degradation of p53. The MDM2 SNP T309G polymorphism (rs2279744) localized in the intronic promoter region of MDM2, affects the affinity of stimulatory protein (Sp1) with the promoter of MDM2, regulating its transcription (Bond et al., 2004) . In the cell model, the MDM2 SNP309G/G genotype shows elevated MDM2 transcription and expression, resulting in attenuation of the p53 pathway and accelerating tumor formation (Bond et al., 2004) . It has been reported that the association of MDM2 SNP309 with various cancers and the correlation between MDM2 expression with poor prognosis (Hirata et al., 2007; Cescon et al., 2009; Toffoli et al., 2009) ; however, the association of MDM2 SNP309 with HCC is inconsistent between studies (Dharel et al., 2006; Yoon et al., 2008; Leu et al., 2009) .
Given the crucial importance of p53 Arg72Pro and MDM2 SNP309 to the risk of malignancy, and the previously observed biological and clinical effects of p53 Arg72Pro and MDM2 SNP309, we evaluated the association between these SNPs with the risk of HBV-related HCC and prognosis in a large cohort of HCC patients with chronic hepatitis B.
RESULTS

Characteristics of HCC patients and HBV carrier controls
The clinicopathologic features of the 580 cases with chronic HBV infection and 96 healthy controls are given in Table 1 . Gender and AFP ≥20 ng/mL were significantly different between HCC patients and the other two groups without HCC (HBV carrier controls and healthy controls). Age and Child-Pugh classification were not significantly different between HCC patients and the other two groups without HCC (HBV carrier controls and healthy controls).
Hardy-Weinberg equilibrium (HWE)
The HWE distribution for the genotype frequencies of p53 Arg72Pro and MDM2 SNP or p53 Arg72Pro and MDM2 SNP 309 was not significantly different in the HCC group, the non-HCC group or in the healthy controls. The genotype distribution in HBV cases and healthy controls was not significantly different and both were consistent with the HWE distribution.
p53 Arg72Pro and MDM2 SNP309 distributions
We examined the p53 Arg72Pro and MDM2 SNP309 distributions for all 676 subjects using the TaqMan SNP genotyping method. The distributions of the p53 Arg72Pro and MDM2 SNP309 genotypes with regard to the presence or absence of HCC are given in Tables S1 and S2 , respectively, with genotyping data for the 96 healthy subjects for comparison. There were lower Arg/Arg (29.43% vs. 37.39%), and higher Pro/Pro genotypes (20.86% vs. 15.22%) distributed in the HCC group compared to the non-HCC group. In comparison to the Arg/Arg genotype, the crude OR (95% CI) of the presence of HCC for the Pro/Pro genotype was 1.74 (range 1.06-2.85; P = 0.028), and the adjusted OR (95% CI) was 1.88 (range 1.07-3.32; P = 0.029). The frequencies of the Child-Pugh classification of severity of liver disease according to the degree of ascites, the plasma concentrations of bilirrubin and albumin, the prothrombin time, and the degree of encephalopathy. This score employs five clinical measures of liver disease. Each measure is scored 1-3, with 3 indicating most severe derangement. A total score of 5-6 is considered grade A (well-compensated disease); 7-9 is grade B (significant functional compromise); and 10-15 is grade C (descompensated disease).
MDM2 SNP309 genotype in HBV patients and healthy controls were not significantly different. Multivariate logistic regression analysis showed that, in contrast to the T/T genotype, the crude OR (95% CI) for the G/G genotype was 1.03 (range 0.64-1.64; P = 0.920) and the adjusted OR (95% CI) was 1.12 (range 0.65-1.93, P = 0.685). Gene-gene interactions between the MDM2 and p53 polymorphisms were also investigated. The combination of the p53 Pro/Pro and MDM2 G/G genotypes was significantly correlated with the risk of HCC with a crude OR (95% CI) of 3.27 (1.19-9.00; P = 0.022) and an adjusted OR (95% CI) of 3.31 (1.01-10.83; P = 0.047). There was no additional effect when the risk of other combined genotypes was analyzed (Table 2) .
Combined p53 Arg72Pro and MDM2 SNP309 indicates poor prognosis
The median follow-up time for HCC patients was 33.3 months. There were no significant differences in disease-free survival (DFS) or overall survival (OS) with respect to the various p53 genotypes. Similar results were observed for the MDM2 genotypes (data not shown). The effect of combined p53 Pro/Pro and MDM2 G/G on DFS and OS was found to be negatively correlated with 1-, 3-and 5-year DFS rates (53.85%, 30.77%, and 19.24%, respectively for combined p53 Pro/Pro and MDM2 G/G genotypes versus 69.44%, 56.79%, and 51.85%, respectively for the other genotypes; P = 0.006). The 1-, 3-and 5-year survival rates were lower for combined p53 Pro/Pro and MDM2 G/G genotype patients compared to patients with other genotypes (84.62%, 53.85%, and 42.31% versus 90.12%, 74.07%, and 69.13%, respectively, P = 0.001, Fig. 1A and 1B) .
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The clinicopathologic characteristics of the HCC patients with combined p53 Pro/Pro and MDM2 G/G genotypes and the other genotypes are given in Table 3 . Tumor size was significantly larger in patients with combined p53 Pro/Pro and MDM2 G/G genotypes (9.66 ± 4.99 cm) compared to other genotypes (6.55 ± 4.03 cm) (P = 0.035). The proportion of complete tumor encapsulation was significantly lower in patients with combined p53 Pro/Pro and MDM2 G/G genotypes compared to other genotypes (38.46% versus 62.65%, P = 0.015). A descriptive Cox proportional hazard model was used to estimate the independent impact of each variable on DFS and OS. Univariate analysis showed that combined p53 Pro/Pro and MDM2 G/G genotypes, AFP expression level, tumor encapsulation, vascular invasion, satellite nodules, tumor differentiation, tumor size and liver cirrhosis were each significantly associated with shorter DFS (Table 4) , and combined p53 Pro/Pro and MDM2 G/G genotypes, AFP expression level, tumor encapsulation, vascular invasion, satellite nodules, tumor differentiation, and tumor size were associated with shorter OS (Table 4) . Finally, multivariate Cox regression analysis showed that combined p53 Pro/Pro and MDM2 G/G genotypes (hazard ratio (HR) = 1.76; P = 0.016), AFP expression level (HR = 1.41; P = 0.036), vascular invasion (HR = 1.57; P = 0.006), satellite nodules (HR = 1.61; P = 0.010), tumor differentiation (HR = 2.12; P = 0.012), and tumor size (HR = 2.09; P < 0.001) were predictive of shorter DFS (Table 4) . Combined p53 Pro/Pro and MDM2 G/G genotypes (hazard ratio (HR) = 1.86; P = 0.017), satellite nodules (HR = 1.78; P = 0.009), and tumor size (HR = 1.95; P = 0.002) were predictive of shorter OS (Table 4) .
Impact of combined p53 Arg72Pro and MDM2 SNP309 on prognosis of HCC patients with different Barcelona Clinic Liver Cancer (BCLC) stages
All 350 patients were stratified according to BCLC classification. A total of 268 HCC patients were classified as stage A. Among these patients, 17 were identified as having combined p53 Pro/Pro and MDM2 G/G genotypes, and 251 were identified with other genotypes. Patients with both p53 Pro/Pro and MDM2 G/G genotypes had a poorer surgical prognosis compared to those with other genotypes (58.82%, 41.18%, and 29.41% versus 79.68%, 66.13%, and 60.96% for 1-, 3-, and 5-year DFS rates, respectively; P = 0.042; 82.35%, 52.94%, and 41.18% versus 96.01%, 80.88%, and 74.90% for 1-, 3-, and 5-year survival rates, respectively; P = 0.001; Fig. 1C and 1D ). All 268 BCLC stage A patients were stratified into two subgroups according to tumor size, using 5 cm as the cutoff value. Patients with tumors > 5 cm in diameter (n = 114) had a poorer prognosis than those with tumors ≤ 5 cm in diameter (n = 154) (66.67%, 54.39%, and 49.12% versus 87.01%, 72.08%, and 66.23% for 1-, 3-, and 5-year DFS rates, respectively; P = 0.001; 92.11%, 69.30%, and 64.91% versus 97.40%, 86.36%, and 78.57% for 1-, 3-, and 5-year survival rates, respectively; P = 0.002). Furthermore, the impact of combined p53 Pro/Pro and MDM2 G/G on the prognoses of the two subgroups was examined. The prognosis of patients in the > 5 cm subgroup (n = 10) with both p53 Pro/Pro and MDM2 G/G genotypes was poorer than for patients (n = 104) with other genotypes (40.00%, 20.00%, and 10.00% versus 69.23%, 57.69%, and 52.88% in 1-, 3-, and 5-year DFS rates, respectively; P = 0.006; 80.00%, 30.00%, and 20.00% versus 93.90%, 73.08%, and 69.23% for 1-, 3-, and 5-year survival rates, respectively; P < 0.001, Fig. 2A and  2B ). In the ≤5 cm subgroup, however, there were no significant differences in cumulative DFS or OS rates between patients with both p53 Pro/Pro and MDM2 G/G genotypes (n = 7) and patients with other genotypes (n = 147) (P = 0.873 for DFS and P = 0.770 for OS, Fig. 2C and 2D) . Similar results were also observed in BCLC B and C stage patients (P = 0.730 for DFS and P = 0.819 for OS, Fig. S1A and S1B).
DISCUSSION
In this study, we confirmed the p53 Pro72 genotype is associated with higher risk of HBV-related HCC. Furthermore, we showed the combination of p53 and MDM2 polymorphisms is related to the oncogenesis, tumor progression and clinical outcome of HBV-related HCC after hepatic resection. We asked whether there was a statistical gene-gene interaction between the MDM2 and p53 polymorphisms. Combined effects of p53 Arg72Pro and MDM2 SNP309 have been examined in lung cancer, nasopharyngeal carcinoma and non-polyposis colorectal cancer, with different results (Zhang et al., 2006; Talseth et al., 2007; Xiao et al., 2010) . In this study, these two polymorphisms produced a combined effect on HCC risk in chronic HBV infection patients. The presence of both the p53 Pro/Pro and MDM2 G/G genotypes resulted in a positive synergistic effect on the risk of HCC, with an adjusted OR (95% CI) of 3.31 (1.01-10.83, P = 0.047), whereas those who lacked both genotypes did not show a positive combined effect on the risk of HCC. Functional difference of the p53 polymorphism at codon 72 has been reported and the Arg72 variant induces apoptosis markedly better than the Pro/Pro genotype (Baptiste et al., 2002; Dumont et al., 2003; Cescon et al., 2009) . In contrast, the Pro72 form appears to induce a higher level of G1 arrest than the Arg72 form. In addition, the MDM2 SNP309 G/G genotype results in elevated MDM2 mRNA and protein expression level and subsequently attenuated tumor suppresses function of p53. A multiplicative interaction is to be expected if a cell carries both p53 Pro/Pro and MDM2 G/G polymorphisms, which heighten the expression of MDM2 and diminish the function of p53. In this study, we showed that the combination of p53 Pro/Pro and MDM2 G/G genotypes was associated with poorer prognosis in HCC patients after liver resection. Kaplan-Meier analysis of DFS and OS in all HCC subjects showed that both tumor recurrence and survival rates differed substantially between patients with both p53 Pro/Pro and MDM2 G/G genotypes and those who lacked both genotypes. Multivariate analysis revealed that having both p53 Pro/Pro and MDM2 G/G genotypes was an independent and significant risk factor affecting recurrence and survival after curative resection. In addition, tumor size was significantly larger and the proportion of complete tumor encapsulation was significantly lower in patients with combined p53 Pro/Pro and MDM2 G/G genotypes compared to other genotypes. These results suggest that the combined p53 Pro/Pro and MDM2 G/G genotypes were associated with malignant characteristics of HCC.
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According to the BCLC staging system, stage A is considered the early stage of HCC. However, some stage A patients still have a poor prognosis in clinical practice. Our results suggest that stage A patients with both p53 Pro/Pro and MDM2 G/G genotypes could have higher cumulative recurrence rates and lower survival rates than those without both genotypes. Because a solitary tumor > 5.0 cm in diameter might affect a patient's prognosis, we stratified the 268 stage A patients with a single nodule in our study into two subgroups, with a cutoff value of 5 cm (Yang et al., 2009) . Having both p53 Pro/Pro and MDM2 G/G genotypes also predicted higher cumulative recurrence rates and lower survival rates in 114 stage A patients with solitary tumor size > 5 cm in diameter ( Fig. 2A and 2B) . Although the stage A patients with a single tumor measuring > 5 cm in diameter suffer from high incidences of recurrence and metastasis after hepatic resection, they are still considered to be candidates for surgery, as noted in previous reports and recommended by the BCLC staging system (Bruix et al., 2001; Yang et al., 2009) . We found that the combination of p53 Pro/Pro and MDM2 G/G genotypes could also significantly affect recurrence and survival in these patients ( Fig. 2A and 2B) . Thus, the results of this study indicate that the combined p53 Pro/Pro and MDM2 G/G genotypes could identify early stage HCC patients with a poorer prognosis, especially for BCLC stage A patients with tumors larger than 5 cm. However, having combined p53 Pro/Pro and MDM2 G/G genotypes did not substantially affect the prognosis of BCLC stage A patients with solitary tumors ≤ 5 cm in diameter after liver resection.
In the present study, the impact of the combination of p53 Pro/Pro and MDM2 G/G genotypes on the prognosis of BCLC stage B+C patients was not significant. This may have been because of the limited number of patients. Additionally, stage B and stage C patients have large multinodular tumors, gross portal vein tumor thrombosis and other invasive features of HCC (Bruix et al., 2001) , and a large proportion of these patients died of tumor recurrence within 2 years (88.89% for combination genotypes of p53 Pro/Pro and MDM2 G/G and 63.34% for the other genotypes). The impact of the combined p53 Pro/Pro and MDM2 G/G genotypes on the outcomes of these patients could thus not be determined.
In summary, we showed that the combination of p53 Pro/Pro and MDM2 G/G genotypes not only resulted in a positive synergistic effect on the risk of HCC, but also substantially affected tumor recurrence and survival in a large cohort of HCC patients. This combined genotype might thus serve as a risk marker of prognosis after liver resection. The results of this work have both diagnostic and prognostic value for HBV-related HCC patients and will help us to understand the relationship between the p53 signaling pathway and HCC.
PATIENTS AND METHODS
Patients
A total of 580 Chinese patients with chronic HBV infection were enrolled in this study. All patients were stratified into two groups according to the presence (n = 350) or the absence (n = 230) of HCC. A total of 360 HCC patients underwent hepatectomies by five independent surgical teams at the Eastern Hepatobiliary Surgery Hospital in Shanghai from December 2003 to June 2009. The preoperative diagnosis of HCC was based on the diagnostic criteria for HCC used by the European Association for the Study of the Liver (EASL) (Bruix et al., 2001) . The postoperative diagnosis of HCC was confirmed pathologically after liver resection. Of the 360 HCC patients, 350 met the following inclusion criteria and thus underwent SNP analysis: preoperative World Health Organization performance status of 0-1; Child-Pugh class A; no distant metastasis; no chemotherapy or radiotherapy before surgery; curative resection; and resected lesions identified as HCC on pathological examination. Five patients had early metastatic disease and/or tumor recurrence within 1 month after resection, three patients received preoperative hepatic arterial chemoembolization, and two patients died from liver failure within 30 days postoperatively. These patients were excluded from this study. A retrospective study was carried out on the remaining 350 HCC patients Curative resection was defined as complete macroscopic and microscopic removal of the tumor. The maximal diameter of the tumor was taken as the tumor size. The resection volume and surgical procedures were designed according to tumor size, location, and liver functional reserves. The clinical staging of tumors was determined according to the BCLC staging systems (Bruix et al., 2001) . The histological grade of tumor differentiation was assigned by the Edmondson Steiner grading system (Edmondson and Steiner, 1954) .
Patients with chronic HBV infection without HCC (non-HCC) were recruited from the Huashan Hospital. All Chronic HBV patients without HCC had a chest X-ray, ultrasonography (USG), and contrast computed tomography (CT) or magnetic resonance imaging (MRI) examination. Laboratory blood tests included hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), hepatitis C virus (HCV) anti body, serum alpha-fetoprotein (AFP), serum albumin, serum total bilirubin, alanine aminotransferase (ALT) and prothrombin time. All chronic HBV patients without HCC were evaluated as HCC-free either radiologically or clinically. All patients were positive for the HBsAg and negative for the HCV antibody detection. To obtain an estimate of the genetic distribution of p53 Arg72Pro and MDM2 SNP309 in the general Chinese population, we obtained blood samples from 96 healthy individuals who visited the Eastern Hepatobiliary Surgery Hospital, with no history of liver disease, negative for both HBsAg and HCV antibody. Written informed consent was obtained from all subjects. There were six patients aged under 18 at the time of enrollment in this study, and their written informed consent was obtained from their guardian. The study was conducted in accordance to the Declaration of Helsinki and Good Clinical Practice guidelines and the protocol was approved by the Institutional Review Board of Eastern Hepatobiliary Surgery Institute, Shanghai, China.
Follow-up and treatment for tumor recurrences
Follow-up ended in June 2011; the median follow-up duration was 33.3 months (range, 1.4-93.7 months). Patients were assessed every 2-3 months within the first 2 years, and then every 3-6 months thereafter. All follow-up examinations were performed by physicians who were unaware of the study. All patients were followed-up for postoperative recurrence with regular assessments using serum AFP, chest x-ray and abdominal USG. A CT or MRI examination was performed every 3 months after surgery. The diagnostic criteria for HCC recurrence were the same as the preoperative criteria. If recurrence was confirmed, recurrent lesions were managed aggressively using a multimodal approach including re-resection, transarterial chemoembolization, percutaneous radiofrequency ablation and percutaneous ethanol injection. The treatment was decided according to the pattern of recurrence, liver functional reserve and general condition of the patient at the time of recurrence.
Genome DNA extraction and allelic discrimination
Genomic DNA was extracted from 200 μL of whole blood using the TIANamp Blood DNA Kit (TIANGEN BIOTECH CO.). The p53 Arg72Pro (rs1042522) and MDM2 SNP309 (rs2279744) SNPs were determined using TaqMan® SNP Genotyping Assays (Applied Biosystems). The primers and probes for genotyping were designed with Primer Express v3.0 software (Applied Biosystems), and manufactured by Applied Biosystems. For p53 Arg72Pro, the amplification primers were: 5′-CCAGATGAAGCTCCCAGAATGC-3′, 5′-GCCGC CGGTGTAGGA-3′. The G allele probe was: 5′-VIC-CTCCCCCCG TG GCC-NFQ-3′. The C allele probe was: 5′-FAM-TCCCCGCGTG GCC-NFQ-3′. For MDM2 SNP309, the amplification primers were: 5′-CGGGAGTTCAGGGTAAAGGT-3′, 5′-ACAGGCACCTGCGATCATC-3′. The G allele probe was: 5′-VIC-CCGCTGCGGCGCG-NFQ-3′. The T allele probe was: 5′-FAM-CCGCTTCGGCGCG-NFQ-3′.
Polymerase chain reaction (PCR) amplification and allelic discrimination were done according to the manufacturer's instructions. In brief, a 5-μL reaction mix was set up for each well of 384-well plates with 20 ng of genomic DNA template. The amplify PCR protocol was: denaturation at 95°C for 10 min, then followed by 50 cycles of 92°C for 15 s and 60°C for 1 min. Endpoint reads and allelic discrimination were done with the 7900HT Fast Real-Time PCR System (Applied Biosystems). Laboratory personnel were blinded to clinical outcome and validation was done with a random 5% of samples.
Statistical analysis
DFS and OS were the primary endpoints. DFS was taken from the date of pathologic diagnosis to the date of earliest recurrence, or censored at last known follow-up. OS was defined as the interval between the date of pathologic diagnosis and death. Outcome data were collected from clinical records and the hospital cancer registries. The last date for censoring purposes was June 2011. For individuals
